Review ArticleYear in Review

2022 Year in Review: Pediatric Asthma

Joyce A Baker
Respiratory Care October 2023, 68 (10) 1430-1437; DOI: https://doi.org/10.4187/respcare.10913

REFERENCES

  1. 1.↵
    Centers for Disease Control and Prevention. Asthma in children. 2019. Available at: https://www.cdc.gov/vitalsigns/childhood-asthma/index.html. Accessed January 14, 2023.
  2. 2.↵
    1. Sullivan PW,
    2. Ghushchyan V,
    3. Navaratnam P,
    4. Friedman HS,
    5. Kavati A,
    6. Ortiz B,
    7. et al
    . The national cost of asthma among school-aged children in the United States. Ann Allergy Asthma Immunol 2017;119(3):246–252.e241.
    OpenUrl
  3. 3.↵
    Centers for Disease Control and Prevention. Asthma stats: Uncontrolled asthma among children, 2012–2014. Available at: https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-children.htm. Accessed January 14, 2023.
  4. 4.↵
    Centers for Disease Control and Prevention. 2020 National health interview survey data. Available at: https://www.cdc.gov/asthma/nhis/2020/data.htm. Accessed January 14, 2023.
  5. 5.↵
    1. Vos T,
    2. Lim SS,
    3. Abbafati C,
    4. Abbas KM,
    5. Abbasi M,
    6. Abbasifard M,
    7. et al
    ; on behalf of GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204–1222.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Johnston NW,
    2. Johnston SL,
    3. Norman GR,
    4. Dai J,
    5. Sears MR
    . The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006;117(3):557–562.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Brunwasser SM,
    2. Snyder BM,
    3. Driscoll AJ,
    4. Fell DB,
    5. Savitz DA,
    6. Feikin DR,
    7. et al
    . Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis. Lancet Respir Med 2020;8(8):795–806.
    OpenUrl
  8. 8.↵
    Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV). Available at: https://cdc.gov/rsv/index.html. Accessed January 14, 2023
  9. 9.↵
    1. Erickson E,
    2. Bhakta RT,
    3. Mendez MD
    . Pediatric bronchiolitis. Treasure Island Florida: StatPearls Publishing; 2023.
  10. 10.↵
    1. Bacharier LB
    . Viral-induced wheezing episodes in preschool children: approaches to therapy. Curr Opin Pulm Med 2010;16(1):31–35.
    OpenUrlPubMed
  11. 11.↵
    1. Garcia-Marcos L,
    2. Mallol J,
    3. Sole D,
    4. Brand PL,
    5. Group ES
    ; EISL Study Group. International study of wheezing in infants: risk factors in affluent and non-affluent countries during the first year of life. Pediatr Allergy Immunol 2010;21(5):878–888.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Shi T,
    2. Ooi Y,
    3. Zaw EM,
    4. Utjesanovic N,
    5. Campbell H,
    6. Cunningham S,
    7. et al
    ; on behalf of the RESCEU Investigators. Association between respiratory syncytial virus–associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis 2020;222(Suppl 7):S628–S633.
    OpenUrl
  13. 13.
    1. Coutts J,
    2. Fullarton J,
    3. Morris C,
    4. Grubb E,
    5. Buchan S,
    6. Rodgers-Gray B,
    7. et al
    . Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol 2020;55(5):1104–1110.
    OpenUrl
  14. 14.↵
    1. Ruotsalainen M,
    2. Heikkila P,
    3. Backman K,
    4. Korppi M
    . An increased asthma risk continued until young adulthood after early-childhood hospitalization for wheezing. Acta Paediatr 2022;111(1):157–162.
    OpenUrl
  15. 15.↵
    1. Meissner HC
    . Viral bronchiolitis in children. N Engl J Med 2016;374(1):62–72.
    OpenUrlCrossRefPubMed
  16. 16.
    1. Choi T,
    2. Devries M,
    3. Bacharier LB,
    4. Busse W,
    5. Camargo CA Jr.,
    6. Cohen R,
    7. et al
    . Enhanced neutralizing antibody responses to rhinovirus C and age-dependent patterns of infection. Am J Respir Crit Care Med 2021;203(7):822–830.
    OpenUrlCrossRef
  17. 17.↵
    1. Wang YC,
    2. Tsai CS,
    3. Yang YH,
    4. Huang KY,
    5. Hsieh WC,
    6. Kuo TY,
    7. et al
    . Association between enterovirus infection and asthma in children: a 16-year nationwide population-based cohort study. Pediatr Infect Dis J 2018;37(9):844–849.
    OpenUrl
  18. 18.↵
    1. Jackson DJ,
    2. Gern JE
    . Rhinovirus infections and their roles in asthma: etiology and exacerbations. J Allergy Clin Immunol Pract 2022;10(3):673–681.
    OpenUrl
  19. 19.
    1. Kusel MM,
    2. de Klerk NH,
    3. Kebadze T,
    4. Vohma V,
    5. Holt PG,
    6. Johnston SL,
    7. et al
    . Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007;119(5):1105–1110.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Brittan MS,
    2. Moss A,
    3. Watson JD,
    4. Federico MJ,
    5. Rice JD,
    6. Dempsey AF,
    7. et al
    . Association between early childhood lower respiratory tract infections and subsequent asthma. J Asthma 2022;59(11):2143–2153.
    OpenUrl
  21. 21.↵
    1. Martinez FD,
    2. Wright AL,
    3. Taussig LM,
    4. Holberg CJ,
    5. Halonen M,
    6. Morgan WJ
    . Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332(3):133–138.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Taussig LM,
    2. Wright AL,
    3. Holberg CJ,
    4. Halonen M,
    5. Morgan WJ,
    6. Martinez FD
    . Tucson children's respiratory study: 1980 to present. J Allergy Clin Immunol 2003;111(4):661–675; quiz 676.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Castro-Rodriguez JA,
    2. Holberg CJ,
    3. Wright AL,
    4. Martinez FD
    . A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000;162(4 Pt 1):1403–1406.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Huffaker MF,
    2. Phipatanakul W
    . Utility of the asthma predictive index in predicting childhood asthma and identifying disease-modifying interventions. Ann Allergy Asthma Immunol 2014;112(3):188–190.
    OpenUrl
  25. 25.↵
    1. Castro-Rodriguez JA,
    2. Forno E,
    3. Padilla O,
    4. Casanello OP,
    5. Krause BJ,
    6. Borzutzky A
    . The asthma predictive index as a surrogate diagnostic tool in preschoolers: analysis of a longitudinal birth cohort. Pediatr Pulmonol 2021;56(10):3183–3188.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Binns E,
    2. Tuckerman J,
    3. Licciardi PV,
    4. Wurzel D
    . Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions. J Paediatr Child Health 2022;58(10):1741–1746.
    OpenUrl
  27. 27.↵
    National Asthma Education and Prevention Program Coordinating Committee. 2020 Focused updates to the Asthma Management Guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020;146(6):1217–1270.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Global Initiative for Asthma (GINA). GINA Report, global strategy for asthma management and prevention. Updated 2022. https://ginasthma.org/gina-reports. Accessed March 1, 2023.
  29. 29.↵
    1. Ducharme FM,
    2. Lemire C,
    3. Noya FJD,
    4. Davis GM,
    5. Alos N,
    6. Leblond H,
    7. et al
    . Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009;360(4):339–353.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.
    1. Kaiser SV,
    2. Huynh T,
    3. Bacharier LB,
    4. Rosenthal JL,
    5. Bakel LA,
    6. Parkin PC,
    7. et al
    . Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics 2016;137(6).
  31. 31.↵
    1. Bacharier LB,
    2. Phillips BR,
    3. Zeiger RS,
    4. Szefler SJ,
    5. Martinez FD,
    6. Lemanske RF Jr.,
    7. et al
    ; CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008;122(6):1127–1135.e1128.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Buendia JA,
    2. Guerrero PD,
    3. Giraldo RJ
    . Cost utility of intermittent inhaled corticosteroids in preschoolers with viral-triggered wheeze. Pediatr Allergy Immunol Pulmonol 2022;35(1):36–42.
    OpenUrl
  33. 33.↵
    1. Chou KJ,
    2. Cunningham SJ,
    3. Crain EF
    . Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995;149(2):201–205.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.
    1. Schuh S,
    2. Johnson DW,
    3. Stephens D,
    4. Callahan S,
    5. Winders P,
    6. Canny GJ
    . Comparison of albuterol delivered by a metered-dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999;135(1):22–27.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Delgado A,
    2. Chou KJ,
    3. Silver EJ,
    4. Crain EF
    . Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children age 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med 2003;157(1):76–80.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Stankovic I,
    2. Pejcic T,
    3. Milenkovic B,
    4. Jovanovic D,
    5. Rancic M
    . Is there any point in a corticosteroid treatment of intermittent asthma? Scientific World Journal 2007;7:1082–1089.
    OpenUrl
  37. 37.↵
    1. Boychuk RB,
    2. Demesa CJ,
    3. Kiyabu KM,
    4. Yamamoto F,
    5. Yamamoto LG,
    6. Sanderson R,
    7. et al
    . Change in approach and delivery of medical care in children with asthma: results from a multi-center emergency department educational asthma management program. Pediatrics 2006;117(4 Pt 2):S145–151.
    OpenUrlPubMedWeb of Science
  38. 38.↵
    1. Engelkes M,
    2. Janssens HM,
    3. de Jongste JC,
    4. Sturkenboom MC,
    5. Verhamme KM
    . Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J 2015;45(2):396–407.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Brown MT,
    2. Bussell JK
    . Medication adherence: WHO cares? Mayo Clin Proc 2011;86(4):304–314.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. De Simoni A,
    2. Horne R,
    3. Fleming L,
    4. Bush A,
    5. Griffiths C
    . What do adolescents with asthma really think about adherence to inhalers? Insights from a qualitative analysis of a UK online forum. BMJ Open 2017;7(6):e015245.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Chipps BE,
    2. Albers FC,
    3. Reilly L,
    4. Johnsson E,
    5. Cappelletti C,
    6. Papi A
    . Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children age ≥ 4 years with moderate-to-severe asthma: rationale and design of the randomized, double-blind, active-controlled MANDALA study. BMJ Open Resp Res 2021;8(1):e001077.
    OpenUrlAbstract/FREE Full Text
  42. 42.
    1. Rodríguez-Martínez CE,
    2. Sossa-Briceno MP,
    3. Buendia JA
    . As-needed use of short-acting β2agonists alone versus as-needed use of short-acting β2 agonists plus inhaled corticosteroids in pediatric patients with mild intermittent (Step 1) asthma: a cost-effectiveness analysis. J Allergy Clin Immunol Pract 2022;10(6):1562–1568.
    OpenUrl
  43. 43.
    1. Camargos P,
    2. Affonso A,
    3. Calazans G,
    4. Ramalho L,
    5. Ribeiro ML,
    6. Jentzsch N,
    7. et al
    . On-demand intermittent beclomethasone is effective for mild asthma in Brazil. Clin Transl Allergy 2018;8:7.
    OpenUrl
  44. 44.↵
    1. Turpeinen M,
    2. Nikander K,
    3. Pelkonen AS,
    4. Syvanen P,
    5. Sorva R,
    6. Raitio H,
    7. et al
    . Daily versus as-needed inhaled corticosteroid for mild persistent asthma (the Helsinki early intervention childhood asthma study). Arch Dis Child 2008;93(8):654–659.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Centers for Disease Control and Prevention. COVID data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed January 15, 2023.
  46. 46.↵
    1. Shekerdemian LS,
    2. Mahmood NR,
    3. Wolfe KK,
    4. Riggs BJ,
    5. Ross CE,
    6. McKiernan CA,
    7. et al
    ; International COVID-19 PICU Collaborative. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020;174(9):868–873.
    OpenUrl
  47. 47.↵
    1. Yonker LM,
    2. Neilan AM,
    3. Bartsch Y,
    4. Patel AB,
    5. Regan J,
    6. Arya P,
    7. et al
    . Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr 2020;227:e45.
    OpenUrl
  48. 48.↵
    1. Leech G,
    2. Rogers-Smith C,
    3. Monrad JT,
    4. Sandbrink JB,
    5. Snodin B,
    6. Zinkov R,
    7. et al
    . Mask wearing in community settings reduces SARS-CoV-2 transmission. Proc Natl Acad Sci U S A 2022;119(23):e2119266119.
    OpenUrlCrossRef
  49. 49.↵
    1. Abrams EM,
    2. Jordan K,
    3. Szefler SJ
    . School asthma care during COVID-19: What we have learned and what we are learning. J Allergy Clin Immunol Pract 2022;10(2):453–459.
    OpenUrl
  50. 50.↵
    1. Boechat JL,
    2. Azevedo C,
    3. Magalhaes O,
    4. Delgado L
    . COVID-19 “infodemics” and asthmatic children: the return to school challenge. J Allergy Clin Immunol Pract 2021;9(7):2940.
    OpenUrl
  51. 51.↵
    Centers for Disease Control and Prevention. Operational guidance for K-12 schools and early care and education programs to support safe in-person learning. Available at: https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-childcare-guidance.html. Accessed March 13, 2023.
  52. 52.↵
    1. Shipp CL,
    2. Gergen PJ,
    3. Gern JE,
    4. Matsui EC,
    5. Guilbert TW
    . Asthma management in children. J Allergy Clin Immunol Pract 2023;11(1):9–18.
    OpenUrl
  53. 53.↵
    1. Martin J,
    2. Townshend J,
    3. Brodlie M
    . Diagnosis and management of asthma in children. BMJ Paediatr Open 2022;6(1):e001277.
    OpenUrl
  54. 54.↵
    1. de Blic J,
    2. Tillie-Leblond I,
    3. Tonnel AB,
    4. Jaubert F,
    5. Scheinmann P,
    6. Gosset P
    . Difficult asthma in children: an analysis of airway inflammation. J Allergy Clin Immunol 2004;113(1):94–100.
    OpenUrlPubMedWeb of Science
  55. 55.
    1. Hauk PJ,
    2. Krawiec M,
    3. Murphy J,
    4. Boguniewicz J,
    5. Schiltz A,
    6. Goleva E,
    7. et al
    . Neutrophilic airway inflammation and association with bacterial lipopolysaccharide in children with asthma and wheezing. Pediatr Pulmonol 2008;43(9):916–923.
    OpenUrlCrossRefPubMed
  56. 56.
    1. Wenzel SE,
    2. Schwartz LB,
    3. Langmack LE,
    4. Halliday JL,
    5. Trudeau JB,
    6. Gibbs RL,
    7. et al
    . Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160(3):1001–1008.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Licari A,
    2. Castagnoli R,
    3. Brambilla I,
    4. Marseglia A,
    5. Tosca MA,
    6. Marseglia GL,
    7. et al
    . Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol 2018;31(2):44–55.
    OpenUrlPubMed
  58. 58.↵
    1. Bush A,
    2. Pavord ID
    . The Lancet Asthma Commission: treating children in primary care. Prescriber 2018;29(11):28–32.
    OpenUrl
  59. 59.↵
    1. Oppenheimer J,
    2. Hoyte FCL,
    3. Phipatanakul W,
    4. Silver J,
    5. Howarth P,
    6. Lugogo NL
    . Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences, and misconceptions. Ann Allergy Asthma Immunol 2022;129(2):169–180.
    OpenUrl
  60. 60.↵
    1. Chung KF
    . Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016;279(2):192–204.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Nair P,
    2. Surette MG,
    3. Virchow JC
    . Neutrophilic asthma: misconception or misnomer? Lancet Respir Med 2021;9(5):441–443.
    OpenUrl
  62. 62.↵
    1. Brown MA,
    2. Jabeen M,
    3. Bharj G,
    4. Hinks TSC
    . Non-typeable haemophilus influenzae airways infection: the next treatable trait in asthma? Eur Respir Rev 2022;31(165):220008.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Hinks TSC,
    2. Levine SJ,
    3. Brusselle GG
    . Treatment options in type 2 low asthma. Eur Respir J 2021;57(1):2000528.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Pavord ID,
    2. Brightling CE,
    3. Woltmann G,
    4. Wardlaw AJ
    . Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353(9171):2213–2214.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    1. Ntontsi P,
    2. Loukides S,
    3. Bakakos P,
    4. Kostikas K,
    5. Papatheodorou G,
    6. Papathanassiou E,
    7. et al
    . Clinical, functional, and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes. Allergy 2017;72(11):1761–1767.
    OpenUrl
  66. 66.↵
    1. Chung KF,
    2. Wenzel SE,
    3. Brozek JL,
    4. Bush A,
    5. Castro M,
    6. Sterk PJ,
    7. et al
    . International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J 2014;43(2):343–373.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Menzies-Gow A,
    2. Wechsler ME,
    3. Brightling CE
    . Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res 2020;21(1):268.
    OpenUrl
  68. 68.↵
    1. Lovinsky-Desir S
    . The use of biologic therapies for the management of pediatric asthma. Pediatr Pulmonol 2020;55(3):803–808.
    OpenUrl
  69. 69.↵
    1. Perikleous EP,
    2. Steiropoulos P,
    3. Nena E,
    4. Paraskakis E
    . Biologic therapies in pediatric asthma. J Pers Med 2022;12(6).
  70. 70.↵
    1. D'Amato G,
    2. Stanziola A,
    3. Sanduzzi A,
    4. Liccardi G,
    5. Salzillo A,
    6. Vitale C,
    7. et al
    . Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidiscip Respir Med 2014;9(1):23.
    OpenUrl
  71. 71.↵
    1. Choy MS,
    2. Dixit D,
    3. Bridgeman MB
    . Mepolizumab (Nucala) for severe eosinophilic asthma. P T 2016;41(10):619–622.
    OpenUrl
  72. 72.↵
    1. Hoy SM
    . Tezepelumab: first approval. Drugs 2022;82(4):461–468.
    OpenUrl
  73. 73.↵
    1. Whittington MD,
    2. McQueen RB,
    3. Ollendorf DA,
    4. Tice JA,
    5. Chapman RH,
    6. Pearson SD,
    7. et al
    . Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol 2017;118(2):220–225.
    OpenUrl
  74. 74.↵
    National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94–138.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. d'Ancona G,
    2. Kavanagh JE,
    3. Dhariwal J,
    4. Hearn AP,
    5. Roxas C,
    6. Fernandes M,
    7. et al
    . Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma. Allergy 2021;76(7):2238–2241.
    OpenUrl
  76. 76.↵
    US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Healthy People 2030, social determinants of health. Available at: https://health.gov/healthypeople/objectives-and-data/social-determinants-health. Accessed January 15, 2023.
  77. 77.↵
    1. Mutic AD,
    2. Mauger DT,
    3. Grunwell JR,
    4. Opolka C,
    5. Fitzpatrick AM
    . Social vulnerability is associated with poorer outcomes in preschool children with recurrent wheezing despite standardized and supervised medical care. J Allergy Clin Immunol Pract 2022;10(4):994–1002.
    OpenUrl
  78. 78.
    United States Environmental Protection Agency. Social vulnerability report. Available at: https://www.epa.gov/cira/social-vulnerability-report. Accessed January 15, 2023.
  79. 79.↵
    1. Zanobetti A,
    2. Ryan PH,
    3. Coull B,
    4. Brokamp C,
    5. Datta S,
    6. Blossom J,
    7. et al
    ; Children's Respiratory and Environmental Workgroup (CREW) Consortium. Childhood asthma incidence, early and persistent wheeze, and neighborhood socioeconomic factors in the ECHO/CREW consortium. JAMA Pediatr 2022;176(8):759–767.
    OpenUrl
  80. 80.↵
    1. Baker JA,
    2. Moore HM,
    3. Brinton JT,
    4. Federico MJ
    . Comprehensive in-patient education consult for asthma exacerbations. Respir Care 2022;67(6):682–687.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    National Association of Community Health Centers. PRAPARE overview. Available at: https://prapare.org. Accessed March 19, 2023.
  82. 82.↵
    Center for Medicare and Medicaid Innovation. The accountable health communities health-related social needs screening tool. Available at: https://innovation.cms.gov/Files/worksheets/ahcm-screeningtool.pdf. Accessed March 13, 2023
  83. 83.↵
    1. Trivedi M,
    2. Pappalardo AA,
    3. Udoko M,
    4. Garg A,
    5. Phipatanakul W,
    6. Szefler SJ,
    7. et al
    . Social determinants of health in asthma through the life course. J Allergy Clin Immunol Pract 2022;10(4):953–961.
    OpenUrl
  84. 84.↵
    1. Lodeserto FJ,
    2. Lettich TM,
    3. Rezaie SR
    . High-flow nasal cannula: mechanisms of action and adult and pediatric indications. Cureus 2018;10(11):e3639.
    OpenUrl
  85. 85.↵
    1. Chauvin-Kimoff L,
    2. DeCaen A
    . Use of high-flow nasal cannula oxygen therapy in infants and children. Paediatr Child Health 2018;23(8):555–556.
    OpenUrl
  86. 86.↵
    1. Rogerson CM,
    2. Carroll AE,
    3. Tu W,
    4. He T,
    5. Schleyer TK,
    6. Rowan CM,
    7. et al
    . Frequency and correlates of pediatric high-flow nasal cannula use for bronchiolitis, asthma, and pneumonia. Respir Care 2022;67(8):976–984.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Nolasco S,
    2. Manti S,
    3. Leonardi S,
    4. Vancheri C,
    5. Spicuzza L
    . High-flow nasal cannula oxygen therapy: physiological mechanisms and clinical applications in children. Front Med (Lausanne) 2022;9:920549.
    OpenUrl
  88. 88.↵
    1. Russi BW,
    2. Lew A,
    3. McKinley SD,
    4. Morrison JM,
    5. Sochet AA
    . High-flow nasal cannula and bi-level positive airway pressure for pediatric status asthmaticus: a single-center, retrospective descriptive and comparative cohort study. J Asthma 2022;59(4):757–764.
    OpenUrl
  89. 89.↵
    1. Al-Subu AM,
    2. Hagen S,
    3. Eldridge M,
    4. Boriosi J
    . Aerosol therapy through high-flow nasal cannula in pediatric patients. Expert Rev Respir Med 2017;11(12):945–953.
    OpenUrl
  90. 90.↵
    1. Li J,
    2. Fink JB
    . Narrative review of practical aspects of aerosol delivery via high-flow nasal cannula. Ann Transl Med 2021;9(7):590.
    OpenUrl
  91. 91.↵
    1. Ari A
    . Effect of nebulizer type, delivery interface, and flow rate on aerosol drug delivery to spontaneously breathing pediatric and infant lung models. Pediatr Pulmonol 2019;54(11):1735–1741.
    OpenUrl
  92. 92.↵
    1. Dugernier J,
    2. Hesse M,
    3. Jumetz T,
    4. Bialais E,
    5. Roeseler J,
    6. Depoortere V,
    7. et al
    . Narrative review of practical aspects of aerosol delivery via high-flow nasal cannula. J Aerosol Med Pulm Drug Deliv 2017;30(5):349–358.
    OpenUrl
  93. 93.↵
    1. Li J,
    2. Zhao M,
    3. Hadeer M,
    4. Luo J,
    5. Fink JB
    . Dose response to trans-nasal pulmonary administration of bronchodilator aerosols via nasal high-flow therapy in adults with stable chronic obstructive pulmonary disease and asthma. Respiration 2019;98(5):401–409.
    OpenUrl
  94. 94.↵
    1. Li J,
    2. Gong L,
    3. Ari A,
    4. Fink JB
    . Decrease the flow setting to improve trans-nasal pulmonary aerosol delivery via “high-flow nasal cannula” to infants and toddlers. Pediatr Pulmonol 2019;54(6):914–921.
    OpenUrl
  95. 95.↵
    1. Li J,
    2. Wei W,
    3. Fink JB
    . In vitro comparison of unit dose vs infusion pump administration of albuterol via high-flow nasal cannula in toddlers. Pediatr Pulmonol 2020;55(2):322–329.
    OpenUrl
  96. 96.↵
    1. Alalwan MA,
    2. Fink JB,
    3. Ari A
    . In vitro evaluation of aerosol drug delivery with and without high flow nasal cannula in children. Pediatr Pulmonol 2019;54(12):1968–1973.
    OpenUrl
  97. 97.↵
    1. Bennett GJ,
    2. Fernandez-Fernandez E,
    3. MacLoughlin R
    . Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy. Intensive Care Med Exp 2019;7(1):20.
    OpenUrl
  98. 98.↵
    1. Li J,
    2. Fink JB,
    3. MacLoughlin R,
    4. Dhand R
    . A narrative review on trans-nasal pulmonary aerosol delivery. Crit Care 2020;24(1):506.
    OpenUrl
  99. 99.↵
    1. Cusack RP,
    2. Satia I,
    3. O'Byrne PM
    . Asthma maintenance and reliever therapy: Should this be the standard of care? Ann Allergy Asthma Immunol 2020;125(2):150–155.
    OpenUrlPubMed
  100. 100.↵
    1. Selroos O
    . A smarter way to manage asthma with a combination of a long-acting beta(2) agonist and inhaled corticosteroid. Ther Clin Risk Manag 2007;3(2):349–359.
    OpenUrlCrossRefPubMed
  101. 101.↵
    1. Reddel HK,
    2. Bateman ED,
    3. Schatz M,
    4. Krishnan JA,
    5. Cloutier MM
    . A practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract 2022;10(1S):S31–S38.
    OpenUrl
  102. 102.↵
    1. Antonio Buendia J,
    2. Lindarte EF,
    3. Patino DG
    . Comparison of three alternatives for the management of moderate asthma in children age 6–11 years: a cost-utility analysis. J Asthma 2022:1–8.
  103. 103.↵
    1. Rodriguez-Martinez CE,
    2. Sossa-Briceno MP,
    3. Nino G
    . Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: a cost-utility analysis in Colombia. J Allergy Clin Immunol Pract 2021;9(10):3816–3818.e2.
    OpenUrl
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords